期刊文献+

口服卡培他滨联合三维适形放疗在胰腺癌治疗中的应用效果分析 被引量:2

The Effect of Oral Administration Capecitabine and 3-Dimensional Conformal Radiotherapy on Patients with Pancreatic Carcinoma
下载PDF
导出
摘要 目的探讨口服卡培他滨联合三维适形放疗在治疗胰腺癌患者的临床应用效果。方法选择2006年1月~2010年12月收治于我院的42例胰腺癌患者,分为研究组和对照组进行研究,研究组患者采用口服卡培他滨联合三维适形放疗进行治疗,对照组仅使用三维适形放疗进行治疗,然后观察并比较两组患者的临床应用效果。结果经过治疗,观察组的总有效率为57.14%,对照组的总有效率为38.09%。结论胰腺癌患者经口服卡培他滨联合三维适形放疗治疗后,其临床疗效较好且无严重副反应,值得临床推广应用。 Objective To evaluate the effect of oral administration capecitabine and 3-dimensional conformal radiotherapy on patients with pancreatic carcinoma.Methods 42 cases with pancreatic carcinoma in our hospital from January 2006 to December 2010 were divided into observation group and control group.Patients in the observation group were treated by oral administration capecitabine and 3-dimensional conformal radiotherapy,patients in the control group were only treated by 3-dimensional conformal radiotherapy,to observe and compare the clinical effects of the two groups.Results After treatment,the total effective rate of the observation group was 57.14%,higher than 38.09% of the control group.Conclusion Oral administration capecitabine and 3-dimensional conformal radiotherapy in treatment of patients with pancreatic carcinoma has high efficacy and few side effects,which is worthy of clinical application.
出处 《临床医学工程》 2011年第8期1212-1213,共2页 Clinical Medicine & Engineering
关键词 卡培他滨 三维适形放疗 胰腺癌 Capecitabine 3-dimensional conformal radiotherapy Pancreatic carcinoma
  • 相关文献

参考文献6

二级参考文献22

  • 1向作林,吴铮,曾昭冲,李文如,王健,陈刚.卡培他滨联合奥沙利铂治疗晚期大肠癌的疗效观察[J].中国临床医学,2004,11(3):386-387. 被引量:10
  • 2周陈华,陈华津,王晓云,叶逢松,叶鸿,陈勇.中晚期肝癌三维适形放疗的临床观察[J].中华放射肿瘤学杂志,2005,14(2):129-130. 被引量:15
  • 3张洪珍,段哲萍,段昕波,吕品田,刘斌.体部伽玛刀治疗原发性肝癌的疗效分析[J].临床肿瘤学杂志,2006,11(12):907-909. 被引量:16
  • 4LOUAFI S, BOIGE V, DUCREUX M, et al. Gemeitabin plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC) : results of a phase Ⅱ study [ J]. Cancer, 2007, 109(7) :1348-1390.
  • 5PARIKH P M, FULORIA J, BABU G, et al. A phase Ⅱ study of gemcitabin and cisplatin in patients with advanced hepatocellular carcinoma [ J ]. Trop C, astroenterol, 2005, 26 ( 3 ) : 115-118.
  • 6TAYEB J, BONYHAY L, GOLLI L, et al. Gemcitabin plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules[J]. Cancer, 2003, 98(12) :2664-2670.
  • 7VENTULINI M. Rational development of capecitabin[ J]. Bur J Cancer, 2002, 2(3) :3-9.
  • 8Zeuli M,Costanzo ED,Sdrobolini A,et al.Capecitabine and oxaliplatin in advanced colorectal cancer:a dose-finding study [J].Ann Oncol,2001,12(12):1737-1741.
  • 9Schuller J,Cassidy J,Dumont E,et al.Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients [ J ].Cancer Chemother Pharmacol,2000,45(4):291-297.
  • 10Sumpter K,Harper-Wynne C,Cunningham D,et al.Oxaliplatin and capecitabine chemotherapy for advanced colorectal cancer:a single institution's experience[J].Clin Oncol (R Coll Radiol),2003,15(5):221-226.

共引文献18

同被引文献21

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部